Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (10mg/kg)
KEYNOTE-010 (P:10 mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated (one line or more) non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells346 / 343high
conclusif
  • demonstrated 39 % decrease in deaths (OS) (PE)
  • suggested 21 % decrease in progression or deaths (PFS) (PE)
KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells151 / 152high
conclusif
  • demonstrated 50 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
  • suggested 45 % decrease in deaths (OS) (extension)
  • suggested 43 % decrease in PFS (extension)
pembrolizumab (2mg/kg)
KEYNOTE-010 (P: 2mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells344 / 343high
conclusif
  • demonstrated 29 % decrease in deaths (OS) (PE)
  • inconclusive 12 % decrease in progression or deaths (PFS) (PE)
KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells139 / 152high
conclusif
  • demonstrated 46 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)